Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterised by a progressive loss of memory and cognitive function, often accompanied by neuropsychiatric symptoms. Because of the insidious, progressive nature of AD, patients typically require assistance for many years, often beginning in the community with family members and/or formal caregivers (e.g. social services) and ending up in residential care.
Hip fractures are also a major cause of disability among older people and result in significant clinical and economic burden and loss of life. Hip fractures account for 20% of orthopaedic bed occupancies in the United Kingdom [1] and the total cost of hip fractures to society is estimated to be ₤726 million per annum (2000 estimates) [2] .
It has been shown that patients with dementia or cognitive impairment who experience a hip fracture are more expensive to treat [3] , more likely to be institutionalised [4, 5] and less likely to recover function [6] [7] [8] compared with patients without dementia or cognitive impairment. Several studies have demonstrated that patients with dementia or cognitive impairment are at an increased risk for fractures compared with patients who are not cognitively impaired [9] [10] [11] [12] [13] [14] . Both AD and hip fracture are common among older people and have associated implications with the independence and future of an individual. However, there is a limited literature concerning whether or not there is a cause-effect relationship between the two.
One study that found an association between AD and hip fracture among women had a cross-sectional design in which the patient's AD status and hip fracture history were determined at the same time, making it difficult to conclude whether a temporal relationship exists [15] . Furthermore, this relationship was not seen among men though this could be the result of a small population size rather than a true lack of association. In another study, hip fractures among AD patients were nearly three times that among age-sex-matched controls [11] . However, it could not be determined from this study if AD was an independent risk factor for the occurrence of a hip fracture because the study did not control for other known risk factors. A study of residents in Canadian health institutions found an independent association between AD and hip fracture although it is unknown whether or not this relationship can be generalised to non-institutionalised patients [14] .
The purpose of this study was to estimate the incidence of hip fracture among AD patients and compare this with an age-sex-matched population without AD and to assess whether an independent relationship between AD and hip fracture exists. The second goal of this study was to compare all-cause mortality rates after the occurrence of a hip fracture between AD patients and patients without AD.
Methods

Study design and setting
The Health Improvement Network (THIN) is an electronic database of computerised longitudinal primary care data collected during routine medical care from nearly 400 general practitioner (GP) offices in the United Kingdom. Data recorded in THIN contains patient demographics, prescriptions, diagnoses, procedures, referrals and hospitalisations.
All AD patients with a presumed date of first diagnosis recorded between 1988 and 2007 were eligible for inclusion in the study population. A patient was considered to have AD if there was a diagnosis code for AD or a prescription for an AD defining drug (i.e. memantine hydrochloride, donepezil hydrochloride, galantamine or rivastigmine) recorded in the patient's electronic medical record. At each AD patient's assumed date of first diagnosis (index date), one patient without AD matched on age (same birth year) and sex registered with the same GP was randomly selected to serve in the reference population.
Patients were excluded from the analysis if they were less than 50 years of age, had incomplete registration information (e.g. missing year of birth, sex, etc.), were registered with a practice that had inadequate data recording quality, were not registered as a permanent patient of a GP or had a history of hip fracture prior to the index date.
Follow-up for each AD patient began at his/her first record of an AD diagnosis or an AD defining drug recorded in the patient's electronic medical record. Follow-up for each non-AD patient began on the same date (index date) as their respective matched AD patient. Follow-up for all patients ended at the first of any of the following events: hip fracture, death, transferral out of the GP practice or the last date of data collection from the GP practice. Patients in the non-AD population were also excluded from contributing person-time to the reference population upon the first date of an AD diagnosis code or prescription for an AD defining drug recorded in the electronic medical record. Therefore, a patient who began follow-up as a member of the non-AD reference population was allowed to cross-over to the AD cohort at the date of an AD-defining event in his/her electronic medical record. A non-AD patient was then randomly selected for such a patient.
Outcomes
The primary outcome of interest was a hip fracture recorded in the GP's electronic medical record during the follow-up period. The secondary outcome of interest was death after hip fracture.
Statistical analysis
We identified all incident hip fractures that occurred during the follow-up period among AD patients and the reference population and estimated incidence rates by 10-year age groups and sex. We estimated the unadjusted incidence rate ratio by comparing the rate observed in the AD patients and the rate observed in the reference population.
Kaplan-Meier survival curves were used to describe the cumulative probability of hip fracture and matched-pair Cox regression analyses were used to estimate the hazard ratio (HR) for hip fractures with adjustment for potential confounders. Interaction terms were added to the regression model and tested for significance; any interaction term with a P-value of ≤0.05 was included in the final regression model. All patients who did not have a missing value for any of the covariates were included in the analysis. Patients who did not have an electronic record for a medical condition or a record for a medication were assumed to have not been diagnosed with the medical condition or prescribed the medication.
We identified all deaths among patients who experienced a hip fracture during the follow-up period. We compared the rate of all-cause mortality after hip fracture among patients with and without AD using unmatched Cox regression analyses adjusting for age and sex as covariates in the model.
All analyses were conducted using SAS v 9.2 and Stata v11.
Results
A total of 10,052 patients with newly diagnosed AD and 10,052 age-sex-matched non-AD patients (supplementary data) from 391 general practices met the inclusion criteria. AD patients contributed an average of 2.2 years of follow-up and non-AD patients contributed an average of 3.4 years. The mean age at AD onset was 79 years (SD = 7.9). Women comprised 65.5% of the study population.
AD patients were more likely to have had a fracture (other than hip fracture) (21.0 versus 18.3%) prior to the index date compared with the non-AD reference population. The non-AD cohort was more likely to have had diabetes (10.1 versus 8.9%), stroke (6.0 versus 4.6%) and heart failure (8.1 versus 6.1%) recorded in the electronic medical records prior to the index date compared with patients with AD. AD patients were more likely to have been prescribed antiepileptics (3.0 versus 2.1%), benzodiazepines (9.4 versus 7.9%), vitamin D (3.5 versus 2.8%), antidepressants (14.1 versus 5.6%) and antipsychotics (7.4 versus 1.9%) in the 6 months prior to the index date. Non-AD patients were more likely to have been prescribed thiazide (19.4 versus 14.4%) and corticosteroids (3.6 versus 2.6%) in the 6 months prior to the index date. Additional results are available in the supplementary data.
Hip fracture analysis
A total of 391 hip fractures occurred among AD patients and 226 occurred among the age-sex-matched non-AD patients. The incidence of hip fracture among patients with and without AD was 17.4 (95% CI, 15.7-19.2) and 6.6 (95% CI, 5.8-7.6) per 1,000 person years, respectively. The unadjusted hazards ratio was 2.8 (95% CI, 2.3-3.6). Table 1 shows the incidence rate of hip fracture by sex and 10-year age group. In both men and women, the incidence rate of hip fracture was consistently higher in patients with AD compared with non-AD patients in all age groups.
One thousand seven hundred and seventy-five subjects were removed from the regression analysis because of missing information on smoking status. In the univariate analyses, the following variables were significantly associated (P ≤ 0.05) with the outcome of a hip fracture: AD, a previous fracture (other than hip fracture), heart failure and a prescription for antipsychotics in the 6 months prior to index date (Table 2) . No interaction terms were found to be significant at the 0.05 level. The association between AD and an increased incidence of hip fracture persisted when potential confounders were adjusted for in the analysis (HR = 3.2; 95% CI, 2.4-4.2). The magnitude of the association between AD and hip fractures was the same in women (HR = 3.3; 95% CI, 2.4-4.6) as it was in men (HR = 3.2; 95% CI, 1.4-7.1). Five years after the index date 7.7% of the AD patients and 3.3% of the non-AD patients had experienced a hip fracture and at nine years 14.5% of AD patients and 5.9% of non-AD patients had experienced a hip fracture (Figure 1a ).
All-cause mortality after hip fracture analysis
The incidence of death among patients who experienced a hip fracture with and without AD was 81.6 (95% CI, 69.9-94.7) and 56.6 (95% CI, 44.8-70.6) per 100 person years, respectively. AD patients who experienced a hip fracture had a 1.5-fold (95% CI, 1.1-1.9) increased mortality rate compared with non-AD patients who experienced a hip fracture after adjusting for age and sex. Among the patients who experienced a hip fracture, 27.2% of AD patients and 13.6% of non-AD patients did not survive more than six months after the occurrence of a hip fracture. Nearly one-third (32.4%) of AD patients and 18.8% of non-AD did not survive more than one year after a hip fracture (Figure 1b ).
Discussion
In this study, we found a threefold increased incidence of hip fractures at any point in time among AD patients compared with patients without AD. Furthermore, AD subjects who experienced a hip fracture had a higher mortality rate compared with the age-sex-matched non-AD patients, a finding that is consistent with results from previous studies [16, 17] .
The main strengths of this study are the longitudinal nature of the data and the large study population. Because the data are collected prospectively in the electronic medical records, we were able to estimate the rates of hip fracture among diagnosed AD patients rather than assessing the AD status and hip fracture history at the same time as was done in another study [15] .
One limitation of this study was that we were not able to determine AD severity from the data in the electronic medical record and relate this to hip fracture risk. A previous study found that the prevalence of hip fracture did vary by dementia severity [15] . Although we selected newly diagnosed patients in an attempt to obtain a mild to moderate AD population, we could not confirm that our cohort was in fact made up of mild to moderate AD patients.
We were also not able to determine the cause of the hip fracture in patients. Most hip fractures occurring in older people are the result of a fall and it has been shown that patients with AD are more likely to fall compared with cognitively healthy older people [18] . It is unclear if AD patients are more prone to fracture a hip after falling due to a higher prevalence of osteoporosis compared with non-AD patients; however, in this study the percent of AD patients and non-AD patients with an electronic record for osteoporosis was small and similar between the two groups (5.8 versus 6.0%) and was not significantly associated with the risk of hip fracture in the univariate or multivariate analysis. The rate of hip fractures increased with lower body mass index (BMI) among both AD patients and non-AD patients (data not shown) though more than half of the subjects in the study did not have a BMI record within 2 years of the index date. Although a low BMI is known to be associated with the occurrence of a hip fracture, we did not include BMI in the regression analysis because accelerated weight loss may be associated with AD [19] and by controlling for BMI we may have been controlling for the effect of AD as well.
Although we could not measure all covariates at baseline it is unlikely that the threefold increase we observed is due to uncontrolled confounding.
The number of older people with both AD and a hip fracture in United Kingdom hospitals accounts for a significant proportion of bed days that people with dementia spend in acute care-and may be the first point for many that AD is diagnosed. Morbidity after hip fracture can lead to increased care needs, even a move to a residential care setting. Such a rapid change in dependency and circumstance lends itself to a preventative strategy. It is not understood what long-term impact the early diagnosis and symptomatic treatment of AD will have on these figures. The study period coincides with the first 10 years of AD treatments in the United Kingdom but is not designed to show any correlation. It may be more interesting as disease modifying treatments become available to test prospectively whether there is any positive impact on the number of falls and hip fractures in AD.
The National Institute for Clinical Excellence guidance on falls states that cognitive impairment is a risk factor for falls but does not include any prevention guidance in this area [20] . Whether or not an increase in falls among AD patients completely explains the increased risk of hip fractures among AD patients remains unknown. It could be that people with AD may fall in a way that increases the chance of fracture-for example over-reaching due to the visuospatial deficits. This clearly does have preventative implications and warrants further study.
Patients with AD and their caregivers should be advised on how to prevent hip fractures and more attention should be given to AD patients who are undergoing rehabilitation following a hip fracture. Additionally, GPs should consider the additional risk to patients with AD when prescribing medications that are associated with an increased risk of falling. In this study, antiepileptics, benzodiazepines, antidepressants and antipsychotics were associated with an increased risk for hip fracture and were also more likely to be prescribed to AD patients in the 6 months before the index date. Any measure that can reduce hip fracture risk will have a significant impact, not just on the individual, but also their caregivers and the healthcare community as a whole.
Key points
• Patients diagnosed with AD had a higher incidence of hip fracture compared with age-sex-matched patients without AD.
• The increase in hip fracture incidence associated with AD persisted after adjustment for other known risk factors.
• Among those who experienced a hip fracture, AD patients had a higher mortality rate compared with non-AD patients.
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